| 证券代码：300401 | 证券简称：花园生物 | 公告编号：2025-035 | | --- | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | | 浙江花园生物医药股份有限公司 关于"花园转债"回售的第一次提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏 1、回售价格：100.512元/张（含息、税） 2、回售申报期：2025年9月9日至2025年9月15日 8、风险提示：投资者选择回售等同于以人民币100元/张（不含利息）卖出持有的 "花园转债"。截至本公告发出前的最后一个交易日，"花园转债"的收盘价为 131.671元/张。投资者选择回售可能会带来损失，敬请投资者注意风险。 浙江花园生物医药股份有限公司（以下简称"公司"）于2025年9月2日召开2025年 第一次临时股东会及"花园转债"2025年第一次债券持有人会议，审议通过了《关于调 整部分募投项目用途及新增募投项目的议案》。根据《公司向不特定对象发行可转换公 司债券募集说明书》（以下简称"《募集说明书》"）的约定，"花园转债"的附加回 售条款生效。现将" ...

证券日报网讯花园生物9月5日在互动平台回答投资者提问时表示，公司部分可转债募投项目虽因技术优 化、工艺参数调整等原因导致项目整体建设周期有所延长，但项目建设一直在推进中。 （文章来源：证券日报） ...

Group 1 - The company has completed the construction of the "annual production of 6,000 tons of vitamin A powder project" as planned [2] - The "annual production of 5,000 tons of vitamin B6 project" is delayed due to further optimization of technology and enhancement of automation levels, and it is currently in the trial production phase [2]

（文章来源：证券日报） 证券日报网讯花园生物9月5日在互动平台回答投资者提问时表示，截至2025年8月29日，公司股东总户 数为28，198户。 ...

证券日报网讯花园生物9月5日在互动平台回答投资者提问时表示，产品价格的变动对公司业绩的影响需 关注量价关系；公司业绩由公司所有产品共同支撑，请理性评估单一产品对公司整体业绩的影响。 （文章来源：证券日报） ...

Meeting Overview - The seventh board meeting of Zhejiang Huayuan Biological Pharmaceutical Co., Ltd. was held on September 2, 2025, with all nine directors present, and the meeting complied with relevant laws and regulations [1][2]. Resolutions Passed - The board approved the election of Mr. Shao Xujun as the representative director to execute company affairs and serve as the legal representative, with a term lasting until the end of the seventh board's term. The voting results were 9 votes in favor, 0 against, and 0 abstentions [1]. - The board also approved the election of members for the audit committee, including Mr. Shao Xujun, Mr. Yan Jianmiao, and Mr. Li Guowei, with Mr. Li Guowei designated as the committee convener. The term for the audit committee members is the same as that of the seventh board [2]. Background of Elected Members - Mr. Shao Xujun has extensive experience within the Huayuan Group and holds 2.45425 million shares of the company. He is the son-in-law of the actual controller, Mr. Shao Qinxiang, and has not faced any penalties from regulatory bodies [2]. - Mr. Yan Jianmiao is a professor at Zhejiang University and has no shareholding in the company, with no conflicts of interest with major shareholders or management [3]. - Mr. Li Guowei is a professor at Zhejiang University of Finance and Economics and also has no shareholding in the company, maintaining independence from major stakeholders [3][4].

Group 1 - The company held the first bondholders' meeting for the "Garden Convertible Bonds" on September 2, 2025, in accordance with relevant regulations and rules [1][2] - A total of 2 bondholders attended the meeting in person, representing 11,031 bonds with an outstanding principal amount of 1,103,100 yuan, which accounts for 0.09% of the total outstanding bond face value [2] - The meeting adopted a combination of on-site voting and communication voting, with the results indicating that all attending bondholders agreed to the proposals presented [2] Group 2 - The legal opinions provided by Beijing Haotian Law Firm confirmed that the meeting's convening and procedures complied with relevant laws and regulations, and the qualifications of the conveners and attendees were valid [2] - The meeting's voting procedures and results were deemed legal and valid according to the legal opinions [2] - The company will keep the legal opinion document available for review [2]

Group 1 - The company announced the approval of two key resolutions during the 12th meeting of the 7th Board of Directors, including the election of a representative to execute company affairs and the election of members for the audit committee along with the nomination of a convener [2]

Group 1 - The company announced the approval of two key proposals during the first extraordinary general meeting of shareholders in 2025, which include adjustments to the use of part of the raised investment projects and the addition of new investment projects [2] - The company also approved a proposal regarding the revision of certain systems [2]

Company Overview - Garden Bio (SZ 300401) announced on September 2 that its 12th meeting of the 7th board of directors was held, where the agenda included the election of a director to represent the company in executing its affairs [1] Financial Performance - For the year 2024, Garden Bio's revenue composition is as follows: Vitamins account for 65.08% and the pharmaceutical manufacturing sector accounts for 34.92% [1] - As of the report date, Garden Bio has a market capitalization of 7.9 billion [1]